In today’s briefing:
- AMD @ Goldman Sachs Communacopia + Technology Conference 2026. Key Takeaways & Full Transcript
- Reliance Worldwide (RWC AU): Brookfield Firms A$4.75/Share Offer. What Say AussieSuper?
- Micron (MU US) 2QFY: Record Earnings, Crowded Expectations — The Trap Is in the Whisper
- MongoDB’s 70,600-Customer Base Builds A Larger Enterprise Growth Engine!
- Credo Technology’s AI Interconnect Powerhouse — AECs, Optics & Retimers Converge!
- Medtronic’s Risky Split-Off: Limited Hedging, Oversubscription, and Potential Post-Tender Sell-Off Concerns
- Palo Alto Networks’ $20 Billion Security Ambition — Can Platformization Deliver?
- Electra Therapeutics (ETRA) Targets $325 Million IPO to Advance Precision Immunology Pipeline
- Broadcom’s $115 Billion AI Engine — Google, OpenAI & Meta Fuel The Surge!
- IPO Rating: Electra Therapeutics Inc.
AMD @ Goldman Sachs Communacopia + Technology Conference 2026. Key Takeaways & Full Transcript
- AMD raised its 2030 Server CPU Total Addressable Market (TAM) projection from $60 billion to $220 billion, targeting >50% market share as it scales multi-threaded architectures like “Venice”.
- Shifting from isolated CPU/GPU/FPGA product roadmaps to a combined Data Center Roadmap Steering Group. Hardware and software trade-offs are now evaluated holistically to deliver full rack-scale system solutions like Helios.
- AMD targets a >60% CAGR in Data Center revenue and >80% CAGR in AI Data Center revenue over its strategic timeframe, driving overall company growth above 35% annually.
Reliance Worldwide (RWC AU): Brookfield Firms A$4.75/Share Offer. What Say AussieSuper?
- After four weeks of due diligence, Reliance Worldwide Corp (RWC AU), a manufacturer of plumbing components, has now entered into a Scheme Implementation Deed (SID) with Brookfield.
- Terms are A$4.75/share (or US$3.638/share), in cash, a 31.5% premium to undisturbed, unchanged from the Process Deed. Terms are not final.
- The binding SID provides Reliance with a “go shop” provision for 30 days. After AustralianSuper bumped its holding, twice, post-deal-announcement, that might be worthwhile pursuing.
Micron (MU US) 2QFY: Record Earnings, Crowded Expectations — The Trap Is in the Whisper
- Micron guided US$50bn / 86% GM / US$31 EPS; the Street sits on the guide but Goldman’s US$51.9bn / US$32.54 is the bar the crowded long actually has to clear.
- The 29 July SK Hynix template applies: a record print 5% under consensus fell 9.6% and changed nothing; Micron’s FQ4 guide annualised already equals our FY2027E EPS of US$125.
- BULLISH maintained, TP US$1,375 (11× FY2027E EPS US$125); at 7.4× with US$100bn contracted and US$22bn deposits banked, a guidance-level “miss” is an add, not a thesis event.
MongoDB’s 70,600-Customer Base Builds A Larger Enterprise Growth Engine!
- MongoDB reported strong financial and operational results for its second quarter of fiscal year 2027, with total revenue reaching $771.8 million, marking 30% year-over-year growth—the fastest growth since fiscal 2024.
- Atlas, the company’s cloud database service, grew approximately 29% year-over-year for the fifth consecutive quarter, driven primarily by large enterprise customers and expanding momentum in artificial intelligence (AI) workloads.
- The Enterprise Advanced (EA) segment, encompassing self-managed deployments, experienced even stronger growth of 36% year-over-year, partly due to the recent launch of Search and Vector Search capabilities that support AI applications in governed environments.
Credo Technology’s AI Interconnect Powerhouse — AECs, Optics & Retimers Converge!
- Credo Semiconductor reported record first-quarter fiscal 2027 revenue of $479 million, up 10% sequentially and more than doubling year-over-year, marking its seventh consecutive quarter of triple-digit year-over-year growth.
- Non-GAAP gross margin was 68%, in line with guidance.
- Non-GAAP net income reached a record $236 million, up 140% year-over-year and 4% sequentially.
Medtronic’s Risky Split-Off: Limited Hedging, Oversubscription, and Potential Post-Tender Sell-Off Concerns
- Medtronic’s exchange offer allows shareholders to swap MDT shares for MMED shares at a 7.53% premium, expiring October 9.
- Hedging is challenging due to limited borrow availability and high fees, with unhedged positions exposed to volatility risks.
- Odd-lot holders are prioritized in the tender, avoiding proration, while oversubscription is likely, affecting larger positions.
Palo Alto Networks’ $20 Billion Security Ambition — Can Platformization Deliver?
- Palo Alto Networks reported a record fiscal 2026 finish, exceeding fourth-quarter guidance across financial metrics as bookings and platform adoption accelerated.
- Remaining Performance Obligations reached more than $21.2 billion, up 34% year-over-year, while Next-Generation Security ARR increased 63% to $9.1 billion.
- Nearly $1 billion of net new NGS ARR was added during the quarter.
Electra Therapeutics (ETRA) Targets $325 Million IPO to Advance Precision Immunology Pipeline
- Electra Therapeutics, Inc. (ETRA) is preparing to sell approximately 21.67 million shares of common stock on the Nasdaq Global Select Market at an expected price of $14.00 to $16.00 per share.
- At the $15.00 midpoint, the offering would raise approximately $325.0 million and value the clinical-stage biotechnology company at roughly $916.5 million.
- Jefferies, TD Cowen, Evercore ISI and Cantor are serving as joint book-running managers. The shares are expected to begin trading on Friday, September 18, 2026.
Broadcom’s $115 Billion AI Engine — Google, OpenAI & Meta Fuel The Surge!
- Broadcom Inc. reported robust financial results for the third quarter of fiscal year 2026, driven primarily by exponential growth in its AI semiconductor business.
- Consolidated revenue reached a record $29.6 billion, marking an 86% increase year-over-year, while operating income rose 92% to $20.1 billion, with operating margins achieving a record 68%.
- AI semiconductor revenue notably surged 221% year-over-year to $16.7 billion, representing 56% of total revenue and up from 49% in the previous quarter.
IPO Rating: Electra Therapeutics Inc.
- ✓ IPO Prophet Rating: 7.68/10 🏦 Deal Quality & Underwriters: 8.25/10 Electra Therapeutics is a late clinical-stage biotechnology company developing precision medicines that selectively deplete disease-driving immune cells through the signal regulatory protein family.
- Its lead candidate, ipsoprubart, is a first-in-class pan-SIRP antibody designed to target pathological myeloid and T cells while preserving unaffected immune populations.
- Ipsoprubart is being evaluated as a frontline treatment for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition with high mortality and limited treatment options.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
